Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Common Equity (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Common Equity for 10 consecutive years, with -$80.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 131.37% to -$80.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$80.0 million, a 131.37% decrease, with the full-year FY2025 number at -$80.0 million, down 131.37% from a year prior.
  • Common Equity was -$80.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $9.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.1 billion in Q1 2021 to a low of -$80.0 million in Q4 2025.
  • A 5-year average of $411.7 million and a median of $310.9 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 993.61% in 2024, then crashed 131.37% in 2025.
  • Ultragenyx Pharmaceutical's Common Equity stood at $922.6 million in 2021, then plummeted by 61.85% to $352.0 million in 2022, then fell by 21.88% to $275.0 million in 2023, then decreased by 7.27% to $255.0 million in 2024, then crashed by 131.37% to -$80.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Common Equity are -$80.0 million (Q4 2025), $9.2 million (Q3 2025), and $151.3 million (Q2 2025).